“Daratumumab has been safely added to several combination therapies and shown added clinical benefit. Researchers observed no new toxicities with the daratumumab (Darzalex, Janssen) combination compared with standard-of-care carfilzomib (Kyprolis, Amgen), lenalidomide (Revlimid, Celgene) and dexamethasone.ĭata were derived from Landgren O, et al. The combination of daratumumab, carfilzomib, lenalidomide and dexamethasone conferred high rates of minimal residual disease negativity among patients with newly diagnosed multiple myeloma, according to phase 2 study results. If you continue to have this issue please contact to Healio
0 Comments
Leave a Reply. |